The effect of antipyretics on immune response and fever following receipt of inactivated influenza vaccine in young children

被引:11
|
作者
Walter, Emmanuel B. [1 ,2 ]
Hornik, Christoph P. [2 ]
Grohskopf, Lisa [3 ]
McGee, Charles E. [1 ]
Todd, Christopher A. [1 ]
Museru, Oidda I. [4 ]
Harrington, Lynn [1 ]
Broder, Karen R. [4 ]
机构
[1] Duke Univ, Sch Med, Duke Human Vaccine Inst, Durham, NC USA
[2] Duke Univ, Sch Med, Dept Pediat, Duke Clin Res Inst, Durham, NC USA
[3] Ctr Dis Control & Prevent, Influenza Div, Epidemiol & Prevent Branch, Atlanta, GA USA
[4] Ctr Dis Control & Prevent CDC, Immunizat Safety Off, Atlanta, GA USA
关键词
Antipyretics; Fever; Immunity; Influenza; Vaccine; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; FEBRILE SEIZURES; UNITED-STATES; RISK; RECOMMENDATIONS; REACTOGENICITY; ACETAMINOPHEN; PREVENTION; SAFETY;
D O I
10.1016/j.vaccine.2017.10.020
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Antipyretics reduce fever following childhood vaccinations; after inactivated influenza vaccine (IIV) they might ameliorate fever and thereby decrease febrile seizure risk, but also possibly blunt the immune response. We assessed the effect of antipyretics on immune responses and fever following IIV in children ages 6 through 47 months. Methods: Over the course of three seasons, one hundred forty-two children, receiving either a single or the first of 2 recommended doses of IIV, were randomized to receive either oral acetaminophen suspension (n = 59) or placebo (n = 59) (double-blinded) or ibuprofen (n = 24) (open-label) immediately following IIV and every 4-8 h thereafter for 24 h. Blood samples were obtained at enrollment and 4 weeks following the last recommended IIV dose. Responses to IIV were assessed by hemagglutination inhibition assay (HAI). Seroprotection was defined as an HAI titer >= 1:40 and seroconversion as a titer >= 1:40 if baseline titer <1:10 or four-fold rise if baseline titer >= 1:10. Participants were monitored for fever and other solicited symptoms on the day of and day following IIV. Results: Significant differences in seroconversion and post-vaccination seroprotection were not observed between children included in the different antipyretic groups and the placebo group for the vaccine antigens included in IIV over the course of the studies. Frequencies of solicited symptoms, including fever, were similar between treatment groups and the placebo group. Conclusions: Significant blunting of the immune response was not observed when antipyretics were administered to young children receiving IIV. Studies with larger sample sizes are needed to definitively establish the effect of antipyretics on IIV immunogenicity. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6664 / 6671
页数:8
相关论文
共 50 条
  • [41] Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections
    Ashkenazi, Shai
    Vertruyen, Andre
    Aristegui, Javier
    Esposito, Susanna
    McKeith, David Douglas
    Klemola, Timo
    Biolek, Jiri
    Kuehr, Joachim
    Bujnowski, Tadeusz
    Desgrandchamps, Daniel
    Cheng, Sheau-Mei
    Skinner, Jonathan
    Gruber, William C.
    Forrest, Bruce D.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2006, 25 (10) : 870 - 879
  • [42] Influenza vaccine: progress in a vaccine that elicits a broad immune response
    Isakova-Sivak, Irina
    Stepanova, Ekaterina
    Mezhenskaya, Daria
    Matyushenko, Victoria
    Prokopenko, Polina
    Sychev, Ivan
    Wong, Pei-Fong
    Rudenko, Larisa
    EXPERT REVIEW OF VACCINES, 2021, 20 (09) : 1097 - 1112
  • [43] A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children
    Zhu, Wei
    Higgs, Brandon W.
    Morehouse, Chris
    Streicher, Katie
    Ambrose, Christopher S.
    Woo, Jennifer
    Kemble, George W.
    Jallal, Bahija
    Yao, Yihong
    VACCINE, 2010, 28 (16) : 2865 - 2876
  • [44] Systematic review of fever, febrile convulsions and serious adverse events following administration of inactivated trivalent influenza vaccines in children
    Li-Kim-Moy, J.
    Yin, J. K.
    Rashid, H.
    Khandaker, G.
    King, C.
    Wood, N.
    Macartney, K. K.
    Jones, C.
    Booy, R.
    EUROSURVEILLANCE, 2015, 20 (24)
  • [45] Practice and Child Characteristics Associated With Influenza Vaccine Uptake in Young Children
    Poehling, Katherine A.
    Fairbrother, Gerry
    Zhu, Yuwei
    Donauer, Stephanie
    Ambrose, Sandra
    Edwards, Kathryn M.
    Staat, Mary Allen
    Prill, Mila M.
    Finelli, Lyn
    Allred, Norma J.
    Bardenheier, Barbara
    Szilagyi, Peter G.
    PEDIATRICS, 2010, 126 (04) : 665 - 673
  • [46] Characteristics of Vaccine Failures in a Randomized Placebo-controlled Trial of Inactivated Influenza Vaccine in Children
    Ng, Sophia
    Ni, Michael Y.
    Fang, Vicky Jing
    Ip, Dennis Kai Ming
    Chan, Kwok-Hung
    Leung, Gabriel Matthew
    Peiris, Joseph Sriyal Malik
    Cowling, Benjamin John
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (02) : E63 - E66
  • [47] Immunogenicity and Sustainability of the Immune Response in Brazilian HIV-1-Infected Individuals Vaccinated With Inactivated Triple Influenza Vaccine
    Souza, Thiago Moreno L.
    Santini-Oliveira, Marilia
    Martorelli, Andressa
    Luz, Paula M.
    Vasconcellos, Mauricio T. L.
    Giacoia-Gripp, Carmem B. W.
    Morgado, Mariza
    Nunes, Estevao P.
    Lemos, Alberto S.
    Ferreira, Ana C. G.
    Moreira, Ronaldo I.
    Veloso, Valdilea G.
    Siqueira, Marilda
    Grinsztejn, Beatriz
    Camacho, Luiz A. B.
    JOURNAL OF MEDICAL VIROLOGY, 2016, 88 (03) : 426 - 436
  • [48] The manufacturing process should remain the focus for severe febrile reactions in children administered an Australian inactivated influenza vaccine during 2010
    Li-Kim-Moy, Jean
    Booy, Robert
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2016, 10 (01) : 9 - 13
  • [49] Safety and immunogenicity of an inactivated thimerosal-free influenza vaccine in infants and children
    Nolan, Terry
    Richmond, Peter C.
    McVernon, Jodie
    Skeljo, Maryanne V.
    Hartel, Gunter F.
    Bennet, Jillian
    Basser, Russell L.
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2009, 3 (06) : 315 - 325
  • [50] Immunogenicity, safety and tolerability of inactivated trivalent influenza vaccine in overweight and obese children
    Esposito, Susanna
    Giavoli, Claudia
    Trombetta, Claudia
    Bianchini, Sonia
    Montinaro, Valentina
    Spada, Anna
    Montomoli, Emanuele
    Principi, Nicola
    VACCINE, 2016, 34 (01) : 56 - 60